**Core Concept**
Ileocecal Crohn's disease refers to the inflammatory bowel disease Crohn's disease affecting the terminal ileum and cecum. The management of ileocecal Crohn's disease involves a multidisciplinary approach, combining medical therapy, endoscopic interventions, and surgical options to control symptoms, prevent complications, and improve quality of life.

**Why the Correct Answer is Right**
The correct answer involves the use of **infliximab**, a monoclonal antibody that targets tumor necrosis factor-alpha (TNF-alpha), playing a crucial role in the pathogenesis of Crohn's disease. Infliximab can induce and maintain clinical remission in patients with moderate to severe Crohn's disease, including those with ileocecal involvement. The mechanism of action involves binding to TNF-alpha, preventing its interaction with cell surface TNF receptors, and ultimately reducing inflammation and mucosal healing.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option might be incorrect because the management of ileocecal Crohn's disease often requires a combination of therapies, and relying solely on one treatment approach may not be sufficient.
* **Option B:** This option might be incorrect because the use of corticosteroids in Crohn's disease is limited due to their poor efficacy in maintaining long-term remission and potential side effects.
* **Option C:** This option might be incorrect because the primary goal of treatment in ileocecal Crohn's disease is to induce and maintain clinical remission, rather than solely focusing on reducing symptoms.

**Clinical Pearl / High-Yield Fact**
A key clinical pearl in managing ileocecal Crohn's disease is the importance of early initiation of treatment with biologics, such as infliximab, to prevent complications and improve long-term outcomes.

**Correct Answer: C. Infliximab is the first-line treatment for moderate to severe ileocecal Crohn's disease.**